A detailed history of Amalgamated Bank transactions in Inhibrx, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 1,176 shares of INBX stock, worth $16,663. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,176
Previous 4,250 72.33%
Holding current value
$16,663
Previous $162,000 74.69%
% of portfolio
0.0%
Previous 0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$32.76 - $39.56 $100,704 - $121,607
-3,074 Reduced 72.33%
1,176 $41,000
Q4 2023

Feb 06, 2024

SELL
$14.5 - $38.0 $5,075 - $13,300
-350 Reduced 7.61%
4,250 $162,000
Q2 2023

Aug 11, 2023

SELL
$16.96 - $27.82 $67 - $111
-4 Reduced 0.09%
4,600 $119,000
Q1 2023

May 02, 2023

SELL
$18.45 - $27.14 $15,645 - $23,014
-848 Reduced 15.55%
4,604 $87,000
Q4 2022

Feb 10, 2023

BUY
$20.18 - $33.33 $16,850 - $27,830
835 Added 18.09%
5,452 $134,000
Q3 2022

Nov 09, 2022

BUY
$11.58 - $24.73 $822 - $1,755
71 Added 1.56%
4,617 $83,000
Q2 2022

Aug 15, 2022

BUY
$8.52 - $25.26 $8 - $25
1 Added 0.02%
4,546 $52,000
Q1 2022

Jun 30, 2022

SELL
$19.89 - $43.18 $7,617 - $16,537
-383 Reduced 7.77%
4,545 $101,000
Q4 2021

Feb 15, 2022

BUY
$26.75 - $46.02 $131,824 - $226,786
4,928 New
4,928 $215,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $553M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.